<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000386239</org_study_id>
    <secondary_id>UCLA-0403067-01</secondary_id>
    <secondary_id>NOVARTIS-CPTK7870113</secondary_id>
    <nct_id>NCT00091299</nct_id>
  </id_info>
  <brief_title>Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label, Non Randomized , One Sequence, Add-On Study to Investigate the Effects of PTK787/ZK 222584 on the Pharmacokinetics and Pharmacodynamics of Warfarin at Steady-States in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vatalanib may stop the growth of tumor cells by stopping blood flow to the tumor.&#xD;
      Warfarin may be effective in preventing the formation of blood clots in patients who are&#xD;
      undergoing treatment for advanced solid tumors.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying how well giving warfarin together with vatalanib&#xD;
      works in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the acute and chronic changes in INR in patients with advanced solid tumors&#xD;
           treated with low-dose warfarin and vatalanib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the steady-state pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
        -  Pharmacokinetic (PK) phase: Patients receive oral low-dose warfarin once daily on days&#xD;
           1-14 and oral vatalanib once daily, 1 hour before warfarin administration, on days 2-14&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Continuation phase: Patients not experiencing a drug interaction in the PK phase&#xD;
           continue to receive oral vatalanib and oral low-dose warfarin once daily. Patients&#xD;
           experiencing a drug interaction (INR &gt; 2.0) in the PK phase receive oral vatalanib alone&#xD;
           once daily. Continuation therapy continues indefinitely in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate acute and chronic changes in INR when Warfarin is co-administered with PTK787/ZK 222584</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the steady state pharmacokinetics of (R) and (S) Warfarin when co-administered with PTK787/ZK 222584</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of low dose warfarin when co-administered with PTK787/ZK 222584</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor&#xD;
&#xD;
          -  Progressed despite standard therapy OR no known standard therapy exists&#xD;
&#xD;
             -- Currently receiving OR a candidate for prophylactic low-dose warfarin (1 mg/day)&#xD;
&#xD;
          -  INR ≤ 1.4&#xD;
&#xD;
          -  Must be an extensive metabolizer of CYP2C9 (at least 1 wild type allelle: *1)&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
               -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
               -  Hepatitis B surface antigen negative&#xD;
&#xD;
               -  Hepatitis C antibody negative&#xD;
&#xD;
               -  Creatinine ≤ 1.5 ULN OR&#xD;
&#xD;
               -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  More than 14 days since prior anticancer chemotherapy&#xD;
&#xD;
          -  More than 14 days since prior anticancer hormonal therapy&#xD;
&#xD;
          -  More than 14 days since prior anticancer radiotherapy&#xD;
&#xD;
          -  More than 14 days since other prior anticancer therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No ethanol for 2 days prior to and for the first 17 days of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No poor metabolizers of CYP2C9 (2 alleles of either *2 or *3)&#xD;
&#xD;
          -  brain metastases&#xD;
&#xD;
          -  history of or active coagulation disorders&#xD;
&#xD;
          -  significant risk for bleeding&#xD;
&#xD;
          -  uncontrolled high blood pressure (BP), defined as diastolic BP &gt; 90 mm Hg or systolic&#xD;
             BP &gt; 140 mm Hg&#xD;
&#xD;
          -  history of cerebral or aortic aneurysm&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  recent history or evidence of drug or alcohol abuse&#xD;
&#xD;
          -  active peptic ulcer disease or gastrointestinal bleeding&#xD;
&#xD;
          -  contraindication or allergy to warfarin or related compounds&#xD;
&#xD;
          -  risk for adverse events related to prolonged PT/PTT due to warfarin administration&#xD;
&#xD;
          -  other medical condition that would preclude study participation&#xD;
&#xD;
          -  concurrent chemotherapy&#xD;
&#xD;
          -  concurrent hormonal therapy&#xD;
&#xD;
          -  concurrent radiotherapy&#xD;
&#xD;
          -  other concurrent CYP2C9 substrates or inhibitors&#xD;
&#xD;
          -  concurrent CYP3A4 inducers or inhibitors&#xD;
&#xD;
          -  concurrent food or dietary supplement known to alter the metabolism of CYP3A4 (e.g.,&#xD;
             grapefruit or Hypericum perforatum [St. John's wort])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel R. Hecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

